Technical Analysis for SUPN - Supernus Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 34.19 3.67% 1.21
SUPN closed up 3.67 percent on Monday, March 18, 2024, on 1.16 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Golden Cross Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
NR7 Range Contraction 3.67%
Overbought Stochastic Strength 3.67%
Stochastic Sell Signal Bearish 2.46%
Upper Bollinger Band Walk Strength 2.46%
Inside Day Range Contraction 2.46%
Overbought Stochastic Strength 2.46%

   Recent Intraday Alerts

Alert Time
Up 3% about 20 hours ago
60 Minute Opening Range Breakout about 20 hours ago
Up 2% about 20 hours ago
Rose Above Previous Day's High about 20 hours ago
Outside Day about 20 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Supernus Pharmaceuticals, Inc. Description

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Drug Discovery Clinical Research Clinical Trial Chloride Epilepsy Depression Neurology Attention Deficit Hyperactivity Disorder Clinical Trial Product Central Nervous System Disease Hyperactivity Disorder Treatment Of Depression Treatment Of Epilepsy Investigational New Drug Treatment Of Central Nervous System Diseases

Is SUPN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 39.09
52 Week Low 22.0
Average Volume 373,073
200-Day Moving Average 29.12
50-Day Moving Average 29.20
20-Day Moving Average 30.98
10-Day Moving Average 32.39
Average True Range 1.41
RSI (14) 66.89
ADX 18.98
+DI 28.87
-DI 11.78
Chandelier Exit (Long, 3 ATRs) 30.59
Chandelier Exit (Short, 3 ATRs) 30.51
Upper Bollinger Bands 34.82
Lower Bollinger Band 27.15
Percent B (%b) 0.92
BandWidth 24.75
MACD Line 1.38
MACD Signal Line 1.08
MACD Histogram 0.2964
Fundamentals Value
Market Cap 1.87 Billion
Num Shares 54.6 Million
EPS 0.42
Price-to-Earnings (P/E) Ratio 81.40
Price-to-Sales 2.50
Price-to-Book 1.67
PEG Ratio 1.47
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 36.82
Resistance 3 (R3) 36.57 35.43 36.38
Resistance 2 (R2) 35.43 34.76 35.56 36.24
Resistance 1 (R1) 34.81 34.35 35.12 35.07 36.09
Pivot Point 33.68 33.68 33.83 33.81 33.68
Support 1 (S1) 33.06 33.01 33.37 33.31 32.29
Support 2 (S2) 31.92 32.59 32.05 32.14
Support 3 (S3) 31.30 31.92 32.00
Support 4 (S4) 31.56